Experimental Study Of Deferasirox Improve The Growth Of Micrangium Through Epithelial-Mesenchymal Transition

Objective To study the function of Deferasirox in improving the growth of micrangium in Narrow Pedicle Flap through Epithelial-Mesenchymal Transition.Methods A total of32male rats were done in our experiments which were separated into experimental group (group Ⅰ) and control group (group Ⅱ).16rats in group Ⅰ were fed with Deferasirox for7days before transferring the Narrow Pedicle Flap orthotopically;16in group II were just fed with saline for7days before transferring the Narrow Pedicle Flap orthotopically. On the third postoperative day, the experiments of quantitative reverse transcription-PCR (qPCR) were done to examine the expression of HIF-1a. IHC and ELISA were done to examine expression of CD34which is on behalf of the density of bloods vessels. And the experiment of IHC and Western Blot were also done to examine the expression of E-cadherin and vimentin. The statistical data were treated to figure out the flap survival rate and determine whether statistical differences lie in the neovascularized microvessel density (MVD) in the flaps.Results The Deferasirox group exhibited a marked improvement in flap healing time and with the increasing administration time of Deferasirox. Flaps in group I were with no necrosis, and the survival rate was100%. While the8/32rat flap in group II were with varying degree of necrosis, and the survival rate was75%. The percentages of survival areas in group I and group Ⅱ were (100±0.00)%and (89.75±10.18)%. The real-time fluorescence quantitative PCR detection of HIF-la in group I was higher than in groupⅡ with statistically significant. The relative value of HIF-1a in group I and group Ⅱ were0.019±0.0017and0.006±0.00013separately with statistically signaficant (P <0.05). Immunohistochemistry and Western blot analysis shows E-cadherin in group I is lower than in group Ⅱ, but positive for vimentin, a statistically significant difference between the two groups (P<0.05). the expression of CD34examined by ELISA in the two group were also with statistically significant,17.63±0.71IU/ml in group and11.21±0.46IU/ml in group Ⅱ, a statistically significant difference between the two groups (P <0.05). Microvessel density in treatment group were40.45±2.78/mm2, and19.42±3.18条/mm2in the control group, a statistically significant difference between the two groups (P<0.05).Conclusion New iron chelator-the Deferasirox pretreatment can promote HIF-1a secretion, and induce the change of EMT. The migration ability of epithelial cells and microvessel density in the narrow flaps (MVD) after the Deferasirox pretreatment were also improved. So the pretreatment of Deferasirox can raise the narrow pedicle flap tolerance to hypoxia, reduce the rate of necrosis of the epithelial tissue cells in a hypoxic environment, and can protect the ischemia and hypoxia narrow flaps effectively.